Q1 2025 · 13F-HR
Propel Bio Management, LLCholdings as filed
Filed 2025-05-15 · accession 0000898432-25-000357
$86.1M
Reported value
18
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 72651A207 | PAGP | PLAINS GP HOLDINGS LP-CL | $27.2M | 31.6% | 1,272,360 | Common | SHARED |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS | $9.9M | 11.6% | 30,032 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $9.3M | 10.8% | 228,884 | Common | SHARED |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS I | $7.1M | 8.27% | 1,134,927 | Common | SHARED |
| 004468500 | ACHV | ACHIEVE LIFE SCIENCES INC | $6.5M | 7.61% | 2,453,092 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $5.5M | 6.41% | 11,285,420 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $5.3M | 6.12% | 178,500 | Common | SHARED |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $3.0M | 3.45% | 624,022 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $2.9M | 3.35% | 2,087,139 | Common | SHARED |
| 24661P807 | DCTH | DELCATH SYSTEMS INC | $2.3M | 2.63% | 177,600 | Common | SHARED |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS IN | $2.3M | 2.62% | 183,259 | Common | SHARED |
| 488445206 | ZVRA | ZEVRA THERAPEUTICS INC | $1.3M | 1.57% | 179,874 | Common | SHARED |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS | $1.2M | 1.35% | 1,451,557 | Common | SHARED |
| F5888J116 | MATPF | MAAT PHARMA SACA | $1.0M | 1.21% | 166,423 | Common | SHARED |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $433,802 | 0.50% | 228,317 | Common | SHARED |
| 04746L104 | — | ATHIRA PHARMA INC | $425,296 | 0.49% | 1,492,792 | Common | SHARED |
| 28249U204 | 72C | EIGER BIOPHARMACEUTICALS | $423,000 | 0.49% | 146,381 | Common | SHARED |
| 169CVR016 | — | CHINOOK THERAPEUTICS | $38,500 | 0.04% | 79,357 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.